Greenwich LifeSciences Stock (NASDAQ:GLSI)

Revenue Ownership Financials Chart

Previous Close

$22.11

52W Range

$7.78 - $34.10

50D Avg

$24.73

200D Avg

$18.90

Market Cap

$338.04M

Avg Vol (3M)

$152.69K

Beta

1.38

Div Yield

GLSI Company Profile

Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Sep 25, 2020

Website

GLSI Performance

GLSI Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-19.45M	$-16.01M	$-9.33M
Net Income	$-19.36M	$-15.79M	$-8.89M
EBITDA	$-19.45M	$-15.79M	$-9.32M
Basic EPS	$-1.43	$-1.21	$-0.69
Diluted EPS	$-1.43	$-1.21	$-0.69

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
IRD	Opus Genetics, Inc.
SRZN	Surrozen, Inc.
TVGN	Tevogen Bio Holdings Inc.
AGEN	Agenus Inc.
SEER	Seer, Inc.
HURA	TuHURA Biosciences, Inc.
CGTX	Cognition Therapeutics, Inc.
ONCY	Oncolytics Biotech Inc.
IMMX	Immix Biopharma, Inc.
ATOS	Atossa Therapeutics, Inc.